Canaccord Genuity Reiterates Buy on STAAR Surgical Company (STAA)

By admin | 7 years ago

STAAR Surgical Company (NASDAQ: STAA)‘s stock had its “buy” rating restated by analysts at Canaccord Genuity in a research report issued to clients and investors on Thursday.

Separately, analysts at Northland Securities initiated coverage on shares of STAAR Surgical Company in a research note to investors on Friday, March 2nd. They set an “outperform” rating and a $14.00 price target on the stock.

STAAR Surgical Company traded down 5.18% on Thursday, hitting $9.975. STAAR Surgical Company has a 1-year low of $4.48 and a 1-year high of $11.79. The company has a market cap of $361.1 million and a price-to-earnings ratio of 263.00.

The company last announced its quarterly results on Wednesday, May 2nd. It reported $0.04 earnings per share (EPS) for the previous quarter, beating the Thomson Reuters consensus estimate of $0.03 EPS by $0.01. The company’s quarterly revenue was up 4.4% on a year-over-year basis. Analysts expect that STAAR Surgical Company will post $0.02 EPS next quarter.

STAAR Surgical Company (STAAR) is engaged in developing, producing, and marketing intraocular lenses (IOLs) and other products for minimally invasive ophthalmic surgery.

About the author